Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
Open Access
- 1 August 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (8), 1001-1010
- https://doi.org/10.1016/j.annonc.2020.05.001
Abstract
No abstract availableFunding Information
- Novartis Pharmaceuticals Corporation
This publication has 11 references indexed in Scilit:
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast CancerJAMA Oncology, 2019
- Phosphatidylinositol 3-Kinase, Growth Disorders, and CancerThe New England Journal of Medicine, 2018
- Abstract 1207: A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+/HER2- metastatic breast cancerCancer Research, 2018
- Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.Journal of Clinical Oncology, 2018
- The prognostic value of PI3K mutational status in breast cancer: A meta-analysisJournal of Cellular Biochemistry, 2018
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trialThe Lancet Oncology, 2017
- Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical TrialsMolecular Cancer Therapeutics, 2014
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 StatusJNCI Journal of the National Cancer Institute, 2014
- Comprehensive molecular portraits of human breast tumoursNature, 2012